


566 F.3d 999
United States Court of Appeals,
Federal Circuit.
ALTANA PHARMA AG and Wyeth, Plaintiffs-Appellants,
v.
TEVA PHARMACEUTICALS USA, INC. and Teva Pharmaceuticals Industries, Ltd., Defendants-Appellees,
and
Kudco Ireland Limited and Schwarz Pharma, Inc., Defendants,
and
Sun Pharmaceutical Industries, Ltd. and Sun Pharmaceutical Advanced Research Centre, Ltd., Defendants-Appellees.
No. 2008-1039.
|
May 14, 2009.
Synopsis
Background: Patent owner and exclusive licensee brought action against competitors alleging infringement of patent directed to active ingredient in antiulcer drug. After consolidating the cases, the United States District Court for the District of New Jersey, 532 F.Supp.2d 666, Jose L. Linares, J., denied owner and licensee's motion for a preliminary injunction. Owner and licensee appealed.
 
Holdings: The Court of Appeals, Ward, District Judge, sitting by designation, held that:
 
district court's determination that alleged infringers' obviousness defense had substantial merit was not clearly erroneous, and
 
district court's determination that owner and licensee failed to demonstrate irreparable harm was not clearly erroneous.
 
Affirmed.
 
Newman, Circuit Judge, filed a concurring opinion.
 
Named Expert: Lester A. Mitscher, Ph.D.
